Overview
Dr. Bopaiah, a Consultant Neuro& Spine surgeon at Apollo BGS Hospitals, Mysore. He has rich experience in the field of Neurosurgery.
Work Experience
- Headed the Dept of Neurosurgery, OPEC Hospital, Raichur (150 bedded Super specialty hospital jointly managed by Govt of Karnataka and Apollo Hospitals Group).
- He has an overall experience of 10 years as consultant Neuro and Spine surgeon and has got 9 years experience in Apollo Mysore.
Honors & Awards
- Dilip R., K. S. Bopaiah, Aumir Moin, Jayanth B. N. : Supratentorial Ependymoma : A rare presentation in an Adoloscent, Apollo Medicine 2019, Vol 16, Issue 3, July-September 2019, Pg 161- 163.
- Bopaiah K. S., Shreykumar P. Shah, Delayed accute onset post traumatic sigmoid sinus/ cerebral venous thrombosis, International Surgery Journal 2017 November 4(11), 3765- 3767.
- R.R Ravi, K S Bopaiah, et al. Ravi Rectangle. J. Spinal Surg 2010; 2(2): 415-17
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial, Lancet Online, June 15,2010, DOI:10.1016/S0140-6736(10)60835-5.
- Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients-BMJ, Feb 2008; 336: 425 – 429. Final results of MRC CRASH, a randomized placebo-controlled trial of intravenous corticosteroid in adults with head injury- Outcome at 6months. Lancet 2005; 365:1957-59.
- Effect of intravenous corticosteroid on death within 14 days in 10008 adults with clinically significant head injury: Randomized placebo-controlled trial. Lancet 2004; 364:1321-28.
- Update on progress in the international, multicenter, randomized, controlled trial of corticosteroids after significant head injury (Medical Research Council CRASH Trial) – Current Opinion in Critical Care. 9(2):92-97, April 2003.
- Phase II Project – A prospective study to correlate gene signatures with clinical outcome of Astrocytomas and identification of potential targets at NIMHANS under Council of Scientific & Industrial Research (CSIR), New Delhi.
- BRAIN TRIAL – Bradykinin beta 2 Receptor Antagonist InNeurotrauma Phase II randomized double blind placebo controlled dose finding safety & tolerability trial of XY2405 (Bradykinin beta 2 Receptor Antagonist) as a treatment for Traumatic brain injury.
- CRASH 2 – (Clinical Randomization of an Anti-fibrinolytic in Significant Hemorrhage) Randomized placebo controlled trial of the effect of early transfusion of Tranexamic Acid on death & transfusionrequirement in patients with significant hemorrhage or at risk of significant hemorrhage.
- CRASH 1 – (Corticosteroid Randomization AfterSignificant Head injury) Randomized placebo controlled trial among adults with head injury and impaired consciousness, of the effects of a 48 hour infusion of corticosteroids on death and neurological disability.
Area of Expertise
- Microneurosurgery
- VascularNeurosurgery – Aneurysm / AVM
- Brain / Spinal Tumors
- Paediatric Neurosurgery
- Neuro-endoscopy
- Trauma
